Hun Ju Lee, MD

Articles

Dr. Lee on Potential Challenges With VLS-101 in MCL and DLBCL

February 22nd 2021

Hun Ju Lee, MD, discusses potential challenges with VLS-101 in mantle cell lymphoma and diffuse large B-cell lymphoma.

Dr. Lee on the Potential Utility of Ibrutinib/Cirmtuzumab in MCL

February 16th 2021

Hun Ju Lee, MD, discusses the potential utility of ibrutinib in combination with cirmtuzumab in mantle cell lymphoma.

Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL

January 8th 2021

Hun Ju Lee, MD, discusses the tolerability of ibrutinib plus cirmtuzumab in mantle cell lymphoma and chronic lymphocytic lymphoma.

Dr. Lee on the Safety, Efficacy of Cirmtuzumab/Ibrutinib Combo in MCL

December 24th 2020

Hun Ju Lee, MD, discusses responses to cirmtuzumab plus ibrutinib in patients with mantle cell lymphoma.

Dr. Lee on B-Cell Receptor Targeting in Relapsed/Refractory MCL

June 23rd 2020

Hun Ju Lee, MD, discusses B-cell receptor targeting in relapsed/refractory mantle cell lymphoma.

Dr. Lee on Examining Novel Targets in Lymphomas and Leukemias

June 15th 2020

Hun Ju Lee, MD, discusses novel targets in lymphomas and leukemias.

Dr. Lee on Early Efficacy Data With Cirmtuzumab/Ibrutinib in MCL

June 10th 2020

Hun Ju Lee, MD, discusses early efficacy data from a phase 1b/2 study of the investigational ROR1 inhibitor cirmtuzumab in combination with ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Dr. Lee on the Mechanism of Action of Cirmtuzumab in MCL or CLL

June 9th 2020

Hun Ju Lee, MD, discusses the mechanism of action of the investigational ROR1 inhibitor cirmtuzumab in combination in mantle cell lymphoma and chronic lymphocytic leukemia.

Dr. Lee on the Mechanism of Action of Cirmtuzumab in MCL or CLL

June 8th 2020

Hun Ju Lee, MD, an associate professor of medicine in the Department of Lymphoma & Myeloma and the Jessica and Jeffrey Brue Endowed Professor of Lymphoma Research at The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of the investigational ROR1 inhibitor cirmtuzumab in combination in mantle cell lymphoma and chronic lymphocytic leukemia.

Dr. Lee on Cirmtuzumab/Ibrutinib Dosing in MCL and CLL

June 3rd 2020

Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.